华海药业：获得托伐普坦片药品注册证书

Core Insights - Huahai Pharmaceutical (600521) has received the drug registration certificate for tolvaptan tablets from the National Medical Products Administration [1] - Tolvaptan tablets are indicated for the treatment of hyponatremia and fluid retention caused by heart failure, with an estimated domestic market sales amount of approximately 497 million yuan [1] - The company has invested around 9.51 million yuan in research and development for this product [1] - The approval of the registration certificate will enhance the product line and improve market competitiveness [1]